Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Subscribe To Our Newsletter & Stay Updated